Want to see GILD full AI Analyst Report?
Compare Gilead Sciences (GILD) vs. Competitors
Comparison Results
| Name | Price | Market Cap | P/E Ratio | Yearly Gain | Analyst Consensus | Analyst Price Target | Compare | Top Analysts' Price Target | Smart Score | Follow |
|---|---|---|---|---|---|---|---|---|---|---|
| GILDGilead Sciences | $170.68 | $211.64B | -55.06 | 44.11% | Strong Buy | GILD | ||||
| BMYBristol-Myers Squibb | $62.48 | $127.71B | 13.82 | 36.96% | Moderate Buy | GILD vs BMY | ||||
| JNJJohnson & Johnson | $273.20 | $657.68B | 41.42 | 44.51% | Moderate Buy | GILD vs JNJ | ||||
| MRKMerck & Company | $149.52 | $368.89B | 152.57 | 73.30% | Moderate Buy | GILD vs MRK | ||||
| NVSNovartis | $160.79 | $297.25B | 31.19 | 31.14% | Moderate Buy | GILD vs NVS | ||||
| PFEPfizer | $30.52 | $173.95B | 40.33 | 25.65% | Moderate Buy | GILD vs PFE |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GILD | Gilead Sciences | 170.68 | 48.63 | 39.84% | |
| BMY | Bristol-Myers Squibb | 62.48 | 18.42 | 41.81% | |
| JNJ | Johnson & Johnson | 273.20 | 91.04 | 49.98% | |
| MRK | Merck & Company | 149.52 | 69.38 | 86.58% | |
| NVS | Novartis | 160.79 | 39.31 | 32.36% | |
| PFE | Pfizer | 30.52 | 7.48 | 32.45% |
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts